MET and breast cancer: We observed that FDA approved anti-ErbB1/ErbB2 neratinib (NER) and anti-c-MET cabozantinib (CBZ) inhibited proliferation and metastasis of brain seeking ERBB2+ SKBrM3 and JIMT-1-BR3 BC cell lines and decreased growth of organoids derived from huERBB2-Tg mice.